BR0011407A - Molécula de ácido nucléico isolada, polipeptìdeo de fusão, composição, vetor, sistema de vetor, sistema de vetor hospedeiro, métodos de produzir um polipeptìdeo de fusão. - Google Patents
Molécula de ácido nucléico isolada, polipeptìdeo de fusão, composição, vetor, sistema de vetor, sistema de vetor hospedeiro, métodos de produzir um polipeptìdeo de fusão.Info
- Publication number
- BR0011407A BR0011407A BR0011407-3A BR0011407A BR0011407A BR 0011407 A BR0011407 A BR 0011407A BR 0011407 A BR0011407 A BR 0011407A BR 0011407 A BR0011407 A BR 0011407A
- Authority
- BR
- Brazil
- Prior art keywords
- fusion polypeptide
- vector
- vector system
- modified
- nucleic acid
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 9
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 9
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 9
- 230000004927 fusion Effects 0.000 title abstract 5
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000008728 vascular permeability Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13813399P | 1999-06-08 | 1999-06-08 | |
PCT/US2000/014142 WO2000075319A1 (en) | 1999-06-08 | 2000-05-23 | Modified chimeric polypeptides with improved pharmacokinetic properties |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0011407A true BR0011407A (pt) | 2002-04-02 |
Family
ID=22480568
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0011407-3A BR0011407A (pt) | 1999-06-08 | 2000-05-23 | Molécula de ácido nucléico isolada, polipeptìdeo de fusão, composição, vetor, sistema de vetor, sistema de vetor hospedeiro, métodos de produzir um polipeptìdeo de fusão. |
BRPI0011407A BRPI0011407B8 (pt) | 1999-06-08 | 2000-05-23 | molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0011407A BRPI0011407B8 (pt) | 1999-06-08 | 2000-05-23 | molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão |
Country Status (33)
Country | Link |
---|---|
EP (2) | EP1544299B1 (pt) |
JP (2) | JP4723140B2 (pt) |
KR (1) | KR100659477B1 (pt) |
CN (3) | CN103349781B (pt) |
AT (2) | ATE293164T1 (pt) |
AU (2) | AU779303B2 (pt) |
BE (1) | BE2013C029I2 (pt) |
BR (2) | BR0011407A (pt) |
CA (1) | CA2376379C (pt) |
CY (2) | CY1108883T1 (pt) |
CZ (2) | CZ302689B6 (pt) |
DE (2) | DE60041159D1 (pt) |
DK (2) | DK1183353T3 (pt) |
ES (2) | ES2237429T3 (pt) |
FR (1) | FR13C0028I2 (pt) |
HK (3) | HK1043388A1 (pt) |
HR (1) | HRP20010908B1 (pt) |
HU (3) | HU230159B1 (pt) |
IL (3) | IL146890A0 (pt) |
LT (1) | LTC1183353I2 (pt) |
LU (1) | LU92195I2 (pt) |
ME (2) | ME00024B (pt) |
MX (1) | MXPA01012630A (pt) |
NO (3) | NO330775B1 (pt) |
NZ (1) | NZ515913A (pt) |
PL (1) | PL208247B1 (pt) |
PT (2) | PT1183353E (pt) |
RS (1) | RS50073B (pt) |
RU (1) | RU2265661C2 (pt) |
SK (1) | SK287332B6 (pt) |
UA (1) | UA74146C2 (pt) |
WO (1) | WO2000075319A1 (pt) |
ZA (1) | ZA200110068B (pt) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6710174B2 (en) | 2001-09-13 | 2004-03-23 | Isis Pharmaceuticals, Inc. | Antisense inhibition of vascular endothelial growth factor receptor-1 expression |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
US6833349B2 (en) * | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
DE60219419T2 (de) | 2001-01-19 | 2007-08-16 | Ludwig Institute For Cancer Research | Flt4 (vegfr-3) als ein ziel für krebsdarstellung und anti-krebs-behandlung |
US6734017B2 (en) | 2001-09-28 | 2004-05-11 | Isis Pharmaceuticals, Inc. | Antisense modulation of vascular endothelial growth factor receptor-2 expression |
US8183350B2 (en) | 2002-05-04 | 2012-05-22 | Acorda Therapeutics, Inc. | Compositions and methods for promoting neuronal outgrowth |
WO2004087206A2 (en) * | 2003-03-28 | 2004-10-14 | Regeneron Pharmaceuticals, Inc. | Methods of treating diabetes by blocking vegf-mediated activity |
CA2525782C (en) * | 2003-05-16 | 2019-02-05 | Acorda Therapeutics, Inc. | Degradation of glycosaminoglycans in extracellular matrix to treat cns injury |
US7959914B2 (en) | 2003-05-16 | 2011-06-14 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
WO2004110360A2 (en) | 2003-05-16 | 2004-12-23 | Acorda Therapeutics, Inc. | Proteoglycan degrading mutants for treatment of cns |
WO2004106378A2 (en) * | 2003-05-28 | 2004-12-09 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection by using vegf antagonists |
US7186699B2 (en) | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
EP1631317A2 (en) | 2003-06-06 | 2006-03-08 | Regeneron Pharmaceuticals, Inc. | Use of vegf inhibitors for tumor regression |
US7399612B2 (en) | 2003-06-30 | 2008-07-15 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
AR046510A1 (es) * | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
EP1653992A1 (en) * | 2003-08-06 | 2006-05-10 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist in combination with radiation therapy |
JP4926962B2 (ja) | 2004-05-18 | 2012-05-09 | アコーダ セラピューティクス、インク. | コンドロイチン分解酵素とその安定な製剤の精製法 |
US7750138B2 (en) | 2004-06-08 | 2010-07-06 | Chengdu Kanghong Biotechnologies Co. Ltd. | Angiogenesis-inhibiting chimeric protein and the use |
MXPA06014421A (es) | 2004-06-10 | 2007-05-04 | Regeneron Pharma | Uso de inhibidores de vegf para el tratamiento de cancer humano. |
EP1755645A2 (en) * | 2004-06-18 | 2007-02-28 | Regeneron Pharmaceuticals, Inc. | Vegf inhibitors for the treatment of malignant pleural effusion |
US7378095B2 (en) | 2004-07-30 | 2008-05-27 | Regeneron Pharmaceuticals, Inc. | Methods of treating type I diabetes by blocking VEGF-mediated activity |
JP4944032B2 (ja) | 2004-09-13 | 2012-05-30 | ジェンザイム・コーポレーション | 多量体構築物 |
US20080107648A1 (en) † | 2005-12-16 | 2008-05-08 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with DII4 antagonists |
FR2878749B1 (fr) * | 2004-12-03 | 2007-12-21 | Aventis Pharma Sa | Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives |
EP1877438A2 (en) | 2005-02-02 | 2008-01-16 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a vegf inhibitor |
DK1861116T3 (en) | 2005-03-25 | 2015-11-09 | Regeneron Pharma | VEGF antagonist formulations |
US7485295B2 (en) | 2005-09-26 | 2009-02-03 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
FR2895258B1 (fr) | 2005-12-22 | 2008-03-21 | Aventis Pharma Sa | Combinaison comprenant de la combretastatine et des agents anticancereux |
US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
CN100502945C (zh) * | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
SI2364691T1 (sl) | 2006-06-16 | 2013-08-30 | Regeneron Pharmaceuticals, Inc. | Formulacije antagonista VEGF, primerne za intravitrealno dajanje |
DK2066694T3 (en) | 2006-09-29 | 2016-02-08 | Oncomed Pharm Inc | Compositions and Methods for Diagnosing and Treating Cancer |
CA3009034C (en) | 2006-10-10 | 2020-08-18 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase abci mutants |
FR2918279B1 (fr) * | 2007-07-05 | 2010-10-22 | Aventis Pharma Sa | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan |
CN101575379B (zh) * | 2008-05-09 | 2012-05-30 | 上海抗体药物国家工程研究中心有限公司 | 可溶性vegfr双功能融合受体、其制备方法及用途 |
CA2742241C (en) | 2008-11-03 | 2019-12-10 | Molecular Partners Ag | Binding proteins inhibiting the vegf-a receptor interaction |
CN101838329A (zh) | 2009-03-18 | 2010-09-22 | 嘉和生物药业有限公司 | 抗血管新生融合蛋白 |
EP3072526B1 (en) | 2009-10-16 | 2018-09-26 | Oncomed Pharmaceuticals, Inc. | Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents |
AR081361A1 (es) | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a |
ES2652508T3 (es) | 2010-08-06 | 2018-02-02 | Genzyme Corporation | Composiciones de antagonistas de VEGF y sus usos |
EP3539991A1 (en) * | 2011-01-07 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Method for improving physical properties of antibody |
EP3222285A1 (en) | 2011-01-13 | 2017-09-27 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist to treat angiogenic eye disorders |
JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
KR101397088B1 (ko) | 2011-06-10 | 2014-05-19 | 강원대학교산학협력단 | 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물 |
JO3370B1 (ar) * | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
ES2651521T3 (es) | 2011-12-01 | 2018-01-26 | Innovent Biologics, Inc. | Inhibidores proteicos de las rutas del complemento y de VEGF y métodos de uso de los mismos |
CN103304668B (zh) * | 2012-03-12 | 2015-10-28 | 江苏健德生物药业有限公司 | Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用 |
US10568934B2 (en) | 2012-05-07 | 2020-02-25 | Allergan, Inc. | Method of treating AMD in patients refractory to anti-VEGF therapy |
WO2014006113A1 (en) | 2012-07-03 | 2014-01-09 | Sanofi | Method of treating cancer by effective amounts of aflibercept |
AR093445A1 (es) | 2012-11-14 | 2015-06-10 | Regeneron Pharma | Metodos para tratar el cancer de ovario con antagonistas de dll4 |
JP6408492B2 (ja) | 2013-02-18 | 2018-10-17 | ヴェジェニクス プロプライエタリー リミテッドVegenics Pty Limited | リガンド結合分子およびその使用 |
AR095196A1 (es) * | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
CN104193828B (zh) * | 2013-09-12 | 2017-04-05 | 北京韩美药品有限公司 | 同时阻断her2和vegfr信号通路的重组融合蛋白 |
PL3065761T3 (pl) | 2013-11-05 | 2020-05-18 | Allergan, Inc. | Sposób leczenia schorzeń oczu za pomocą darpinu przeciwko vegf |
JP6802069B2 (ja) | 2014-05-12 | 2020-12-16 | フォーマイコン アーゲーFormycon Ag | Vegf拮抗薬を収容したプレフィルドプラスチックシリンジ |
CN107076750B (zh) | 2014-07-18 | 2020-06-23 | 赛诺菲 | 用于预测疑似患有癌症的患者使用阿柏西普的治疗结果的方法 |
JP2016036322A (ja) * | 2014-08-11 | 2016-03-22 | 日本化薬株式会社 | 血管新生因子と結合するキメラタンパク質 |
CN112826934A (zh) | 2014-12-11 | 2021-05-25 | 拜耳医药保健有限责任公司 | 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗 |
GB201503453D0 (en) | 2015-03-01 | 2015-04-15 | Jain Arjun | Endothelin-1"sponge" |
TWI797060B (zh) | 2015-08-04 | 2023-04-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
WO2017046140A1 (en) | 2015-09-18 | 2017-03-23 | Bayer Pharma Aktiengesellschaft | Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia |
KR101936049B1 (ko) * | 2015-10-15 | 2019-01-08 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 생산방법 |
WO2017065559A1 (ko) | 2015-10-15 | 2017-04-20 | (주)알테오젠 | Igg fc 도메인을 가지는 융합 단백질의 생산방법 |
AU2016358111B2 (en) | 2015-11-18 | 2021-11-18 | Formycon Ag | Pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist |
KR20180083377A (ko) | 2015-11-18 | 2018-07-20 | 포르미콘 아게 | Vegf 안타고니스트를 함유하는 사전충전형 플라스틱 주사기 |
KR20180105123A (ko) | 2015-11-18 | 2018-09-27 | 에스아이오2 메디컬 프로덕츠, 인크. | 안과 제제용 제약 패키지 |
WO2018218013A2 (en) | 2017-05-24 | 2018-11-29 | Sio2 Medical Products, Inc. | Sterilizable pharmaceutical package for ophthalmic formulations |
EP3377101A4 (en) * | 2015-11-19 | 2019-08-07 | Zhuhai Tairuishang Biopharm Ltd. | VEGF BINDING METHODS AND COMPOSITIONS |
LT3384049T (lt) | 2015-12-03 | 2023-09-11 | Regeneron Pharmaceuticals, Inc. | Genetinių variacijų susiejimo su klinikiniais rezultatais būdai pacientams, sergantiems amžine geltonosios dėmės degeneracija, gydytiems anti-vegf |
AU2017213103B2 (en) | 2016-01-26 | 2022-08-11 | Formycon Ag | Liquid formulation of a VEGF antagonist |
US20190300607A1 (en) | 2016-10-12 | 2019-10-03 | Daiichi Sankyo Company, Limited | Composition containing anti-robo4 antibody and other agents |
CN116327963A (zh) | 2016-11-21 | 2023-06-27 | 济世-伊沃泰克生物制品有限公司 | 一种眼科制剂及其用途 |
WO2018215580A1 (en) | 2017-05-24 | 2018-11-29 | Formycon Ag | Method for sterilizing prefilled plastic syringes containing a vegf antagonist |
EP3630043A1 (en) | 2017-05-24 | 2020-04-08 | Formycon AG | Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist |
TW201904610A (zh) | 2017-06-14 | 2019-02-01 | 德商拜耳製藥公司 | 用於治療新生血管型青光眼之非抗體vegf拮抗劑 |
WO2019020777A1 (en) | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
KR102578087B1 (ko) | 2017-08-17 | 2023-09-18 | 저스트-에보텍 바이오로직스, 아이엔씨. | 숙주세포 갈렉틴(galectins) 및 다른 오염물(contaminant)로부터 글리코실화 단백질을 정제하는 방법 |
CA3081094A1 (en) | 2017-11-20 | 2019-05-23 | Alison J. GILLESPIE | Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof |
DK3717636T3 (da) | 2017-11-27 | 2023-05-30 | 4D Molecular Therapeutics Inc | Adeno-associeret-virus-variantcapsider og anvendelse til inhibering af angiogenese |
ES2927049T3 (es) | 2017-11-30 | 2022-11-02 | Regeneron Pharma | Uso de un antagonista del VEGF para tratar trastornos oculares angiogénicos |
CN117405806A (zh) | 2017-12-13 | 2024-01-16 | 里珍纳龙药品有限公司 | 管理层析柱床支架的装置和系统及相关方法 |
BR112020015074A2 (pt) | 2018-01-26 | 2020-12-08 | The Regents Of The University Of California | Métodos e composições para tratamento de transtornos angiogênicos com uso de agentes anti-vegf |
CA3099551A1 (en) | 2018-05-10 | 2019-11-14 | Regeneron Pharmaceuticals, Inc. | High concentration vegf receptor fusion protein containing formulations |
US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
CN111378044B (zh) | 2018-12-28 | 2022-07-15 | 长春金赛药业有限责任公司 | 抗体融合蛋白、制备方法及其应用 |
US20220204920A1 (en) | 2019-05-16 | 2022-06-30 | Formycon Ag | Method for reducing methionine oxidation in recombinant proteins |
US20210060258A1 (en) | 2019-09-03 | 2021-03-04 | Amgen Inc. | Injection device for drug delivery and packaging for the injection device |
WO2021056020A1 (en) | 2019-09-16 | 2021-03-25 | Amgen Inc. | Method for external sterilization of drug delivery device |
CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
KR20220104756A (ko) | 2019-11-25 | 2022-07-26 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 안구내 신생혈관형성을 위한 장기지속형 vegf 억제제 |
CN114786695A (zh) | 2019-12-06 | 2022-07-22 | 瑞泽恩制药公司 | Vegf微型捕捉体及其使用方法 |
MY190624A (en) | 2019-12-06 | 2022-04-27 | Regeneron Pharma | Anti-vegf protein compositions and methods for producing the same |
MX2022010177A (es) | 2020-02-24 | 2022-09-12 | Amgen Inc | Envases y sistemas para su uso durante la esterilizacion externa de dispositivos de administracion de farmacos. |
EP4145456A1 (en) | 2021-09-06 | 2023-03-08 | Bayer AG | Prediction of a change related to a macular fluid |
WO2024029876A1 (ko) * | 2022-08-02 | 2024-02-08 | 주식회사 파노로스바이오사이언스 | 변형된 융합 단백질 및 이의 용도 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9506466D0 (en) * | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
-
2000
- 2000-05-23 RS YUP-869/01A patent/RS50073B/sr unknown
- 2000-05-23 DK DK00932721T patent/DK1183353T3/da active
- 2000-05-23 DE DE60041159T patent/DE60041159D1/de not_active Expired - Lifetime
- 2000-05-23 AT AT00932721T patent/ATE293164T1/de active
- 2000-05-23 ME MEP-2008-32A patent/ME00024B/me unknown
- 2000-05-23 RU RU2002100071/13A patent/RU2265661C2/ru active Protection Beyond IP Right Term
- 2000-05-23 BR BR0011407-3A patent/BR0011407A/pt not_active IP Right Cessation
- 2000-05-23 CA CA002376379A patent/CA2376379C/en not_active Expired - Lifetime
- 2000-05-23 DK DK05001328T patent/DK1544299T3/da active
- 2000-05-23 ES ES00932721T patent/ES2237429T3/es not_active Expired - Lifetime
- 2000-05-23 IL IL14689000A patent/IL146890A0/xx unknown
- 2000-05-23 ES ES05001328T patent/ES2319305T3/es not_active Expired - Lifetime
- 2000-05-23 NZ NZ515913A patent/NZ515913A/xx not_active IP Right Cessation
- 2000-05-23 CZ CZ20014387A patent/CZ302689B6/cs unknown
- 2000-05-23 PL PL352246A patent/PL208247B1/pl active Protection Beyond IP Right Term
- 2000-05-23 CN CN201310118971.1A patent/CN103349781B/zh not_active Expired - Lifetime
- 2000-05-23 PT PT00932721T patent/PT1183353E/pt unknown
- 2000-05-23 BR BRPI0011407A patent/BRPI0011407B8/pt unknown
- 2000-05-23 JP JP2001502582A patent/JP4723140B2/ja not_active Expired - Lifetime
- 2000-05-23 UA UA2001128378A patent/UA74146C2/uk unknown
- 2000-05-23 AU AU50404/00A patent/AU779303B2/en active Active
- 2000-05-23 CZ CZ20100386A patent/CZ303656B6/cs not_active IP Right Cessation
- 2000-05-23 CN CNB008115443A patent/CN100523187C/zh not_active Expired - Lifetime
- 2000-05-23 WO PCT/US2000/014142 patent/WO2000075319A1/en active Application Filing
- 2000-05-23 HU HU1300086A patent/HU230159B1/hu unknown
- 2000-05-23 AT AT05001328T patent/ATE417928T1/de active
- 2000-05-23 EP EP05001328A patent/EP1544299B1/en not_active Expired - Lifetime
- 2000-05-23 DE DE60019415T patent/DE60019415T2/de not_active Expired - Lifetime
- 2000-05-23 KR KR1020017015839A patent/KR100659477B1/ko active Protection Beyond IP Right Term
- 2000-05-23 MX MXPA01012630A patent/MXPA01012630A/es active IP Right Grant
- 2000-05-23 EP EP00932721A patent/EP1183353B1/en not_active Expired - Lifetime
- 2000-05-23 SK SK1752-2001A patent/SK287332B6/sk not_active IP Right Cessation
- 2000-05-23 PT PT05001328T patent/PT1544299E/pt unknown
- 2000-05-23 CN CN2008101093559A patent/CN101433715B/zh not_active Expired - Lifetime
- 2000-05-23 HU HU0201515A patent/HU229156B1/hu active Protection Beyond IP Right Term
- 2000-05-23 ME MEP-32/08A patent/MEP3208A/xx unknown
-
2001
- 2001-12-03 IL IL146890A patent/IL146890A/en active Protection Beyond IP Right Term
- 2001-12-06 ZA ZA200110068A patent/ZA200110068B/xx unknown
- 2001-12-07 HR HR20010908A patent/HRP20010908B1/xx not_active IP Right Cessation
- 2001-12-10 NO NO20016036A patent/NO330775B1/no active Protection Beyond IP Right Term
-
2002
- 2002-07-04 HK HK02105009A patent/HK1043388A1/xx not_active IP Right Cessation
-
2005
- 2005-03-31 AU AU2005201365A patent/AU2005201365B2/en not_active Expired
-
2008
- 2008-03-17 IL IL190234A patent/IL190234A0/en not_active IP Right Cessation
-
2009
- 2009-03-16 CY CY20091100288T patent/CY1108883T1/el unknown
- 2009-11-05 HK HK09110323.8A patent/HK1132653A1/xx unknown
-
2010
- 2010-05-06 NO NO20100656A patent/NO332559B1/no not_active IP Right Cessation
- 2010-10-06 JP JP2010226970A patent/JP5273746B2/ja not_active Expired - Lifetime
-
2013
- 2013-05-13 BE BE2013C029C patent/BE2013C029I2/fr unknown
- 2013-05-13 CY CY2013019C patent/CY2013019I1/el unknown
- 2013-05-14 LU LU92195C patent/LU92195I2/fr unknown
- 2013-05-14 FR FR13C0028C patent/FR13C0028I2/fr active Active
- 2013-05-14 LT LTPA2013009C patent/LTC1183353I2/lt unknown
- 2013-05-15 NO NO2013010C patent/NO2013010I1/no unknown
- 2013-09-17 HU HUS1300052C patent/HUS1300052I1/hu unknown
- 2013-11-26 HK HK13113191.5A patent/HK1185798A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0011407A (pt) | Molécula de ácido nucléico isolada, polipeptìdeo de fusão, composição, vetor, sistema de vetor, sistema de vetor hospedeiro, métodos de produzir um polipeptìdeo de fusão. | |
DE60033138D1 (de) | Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren | |
BR0007414A (pt) | Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc | |
ATE286907T1 (de) | Cytokinin-designiertes lerk-5 | |
BR0113921A (pt) | ácidos nucléicos e polipeptìdeos receptores | |
BR0009392A (pt) | Polipeptìdeo, sequência de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, métodos para produzir uma sequência de ácido nucleico mutante e para produzir um polipeptìdeo, mutante de um polipeptìdeo com atividade de alafa-amilase, e, uso do polipeptìdeo ou variante | |
AU9174398A (en) | Peptides | |
BR0009393A (pt) | Polipeptìdeo, sequência de ácido nucleico isolada, construção de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, método para a produção do polipeptìdeo, uso de um polipeptìdeo, e, composição detergente | |
BR0214350A (pt) | Sequências de ácido nucleico e aminoácido de adenovìrus de sìmio, vetores contendo as mesmas e métodos de uso | |
DE69836092D1 (de) | Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen | |
ATE368682T1 (de) | Als 2f1 bezeichnetes rezeptorprotein | |
DK0973806T3 (da) | Sted-beskyttet proteinmodificering | |
BR9612359A (pt) | Derivado covalente de uma proteína ob composição polipeptídeo quimérico sequência de ácido nucleico vetor de express o replicável célula hospedeira e métodos associados aos mesmos | |
DE60024659D1 (de) | Vektoren und verfahren für rekombinante proteinexpression | |
DE69511399D1 (de) | Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren | |
WO2002062999A8 (en) | Proteins and nucleic acids encoding same | |
WO2002059315A3 (en) | Human nucleic acids and polypeptides and methods of use thereof | |
WO2002046409A3 (en) | Proteins and nucleic acids encoding same | |
WO2001025438A3 (en) | Ifn-alpha homologues | |
WO1994003601A3 (en) | Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan | |
IL142596A0 (en) | Baculovirus expression system | |
DE60139113D1 (de) | 18477, eine menschliche proteinkinase und deren verwendung | |
Jean et al. | Unmasking a hyaluronan‐binding site of the BX7B type in the H3 heavy chain of the inter‐α‐inhibitor family | |
ATE288491T1 (de) | Polypeptide mit 5-aminolevulinsäure synthaseaktivität und deren nukleinsäuren | |
ATE362531T1 (de) | Interne ribosom eintrittstelle (ires), vektor der diesen enthaltet und dessen therapeutische verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 37, 24, 25 DA LPI 9279/06 |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: REAPRESENTAR A PETICAO NO 020120017630 DE 01/03/2012. |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 25/09/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
B22O | Other matters related to patents and certificates of addition of invention: legal action concerning patent |
Free format text: INPI NO 52402.004205/2021-78 ORIGEM: 31O VF DO RIO DE JANEIRO PROCESSO NO: 5031304-25.2021.4.02.5101 NULIDADE DE ATO ADMINISTRATIVO AUTOR: LIBBS FARMACEUTICA LTDA. REU(S): REGENERON PHARMACEUTICALS, INC. E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/05/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 23/05/2020 |